The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS).
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
-
University of Southern California, Los Angeles, California, United States, 90033
Northeast Georgia Medical Center, Gainesville, Georgia, United States, 30501
University of Illinois Chicago, Chicago, Illinois, United States, 60612
Franciscan Health Indianapolis, Indianapolis, Indiana, United States, 46237
Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana, United States, 70808
Dana-Farber Cancer Institute, Boston, Massachusetts, United States, 02215
Cancer and Hematology Centers of Western Michigan, Grand Rapids, Michigan, United States, 49503
Allina Health System dba Virginia Piper Cancer Institute, Saint Paul, Minnesota, United States, 55102
Oncology Hematology Associates, Springfield, Missouri, United States, 65807
Nebraska Cancer Specialists, Omaha, Nebraska, United States, 68130
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 99 Years
ALL
No
Amgen,
MD, STUDY_DIRECTOR, Amgen
2028-09-25